It remains controversial whether patients with papillary thyroid microcarcinoma (PTMC) benefit from total thyroidectomy (TT) or thyroid lobectomy (TL). We aimed to investigate the impact of extent of surgery on the prognosis of patients with unilateral PTMC. Patients were obtained from the Surveillance, Epidemiology, and End Results database from 2004 to 2015. Cancer-specific survival (CSS) and overall survival (OS) were evaluated by Cox regression and Kaplan–Meier curves with propensity score matching. Of 31,167 PTMC patients enrolled, 22.2% and 77.8% of which underwent TL and TT, respectively. Patients with TT were more likely to be younger, females, present tumors of multifocality, extrathyroidal extension, cervical lymph node metastasis (CLNM), distant metastasis, and receive radioactive iodine (RAI) compared with those receiving TL. The multivariate Cox regression model showed that TT was not associated with an improved CSS and OS compared with TL with hazard ratio (HR) and 95% confidence interval (CI) of 0.53 (0.25-1.12) and 0.86 (0.72-1.04), respectively. In addition, the Kaplan–Meier curves further confirmed the similar survival between TL and TT after propensity score matching. The subgroup analysis showed that TT was associated with better CSS for patients < 55 years, those with tumors of gross extrathyroidal extension, CLNM (N1b), and cases not receiving RAI with HR 95% CI of 0.13 (0.02-0.81), 0.12 (0.02-0.66), 0.11 (0.02-0.64) and 0.36 (0.13-0.90), respectively. TT predicted a trend of better OS for patients with N1b and distant metastasis after adjustment. In addition, TT was associated with better CSS than TL for patients with risk factors like N1b combined with gross extrathyroidal extension, and/or multifocality after matching. In conclusion, TL may be enough for low-risk PTMC patients. TT may improve the prognosis of unilateral PTMC patients with 2 or more risk clinicopathologic factors like CLNM, multifocality, extrathyroidal extension and a younger age compared with TL.

Keywords: papillary thyroid microcarcinoma, total thyroidectomy, lobectomy, prognosis, propensity score matching
INTRODUCTION

Papillary thyroid microcarcinoma (PTMC) is defined as a papillary thyroid carcinoma (PTC) ≤ 1.0 cm in diameter, which has been increasingly detected in recent decades across the world with the popularity of ultrasound and fine-needle aspiration cytology (1, 2). PTMC is generally an indolent disease with excellent prognosis (3). Recently, active surveillance has been recommended as an alternative approach for low-risk PTMC according to the American Thyroid Association (ATA) guidelines (4).

Thyroid lobectomy (TL) alone was sufficient for unifocal and intrathyroidal PTMC in the absence of clinically detectable cervical nodal metastasis (4). TL may be appropriate for PTMC patients when no evidence of extrathyroidal disease was found (5). However, the rate of pathological cervical lymph node metastasis (CLNM) was 48.0% for PTC (6), and 42.4% for PTMC when prophylactic central lymph node dissection was performed (7), which does pose a risk for local recurrence (8). Postoperative local lymph node recurrence was associated with reoperations and the consequently excess morbidity from reoperations (9).

Besides TL, total thyroidectomy (TT) is commonly performed on unilateral PTMC patients. TT was associated with more complications like hypocalcemia, recurrent laryngeal nerve injury, and high-dose hormone replacement throughout one’s life. However, it remains unclear whether patients with unilateral PTMC benefit from TL or TT (10). We expect that PTMC patients with risk clinicopathologic features may benefit from more aggressive surgical treatment. However, it remains unclear due to the excellent prognosis of PTMC and limited qualified cases. In this study, we aim to compared the prognosis between patients receiving TT and TL with a large sample size.

PATIENTS AND METHODS

Ethics Statement

The patients were enrolled from the Surveillance, Epidemiology, and End Results (SEER) program (https://seer.cancer.gov/) from 2004 to 2015. This study was deemed exempt by the institutional review board approval for the deidentified patient information.

Study Population

Medical records were drawn using the International Classification of Diseases for Oncology code site C73.9. Histotype of PTC with values of 8050 (papillary carcinoma), 8260 (papillary adenocarcinoma), 8340 (papillary carcinoma, follicular variant), and 8341 (papillary microcarcinoma) were included. Values of 8050, 8260 and 8341 were classified as PTC, and 8340 for follicular variant PTC (FVPTC). The demographic, clinicopathologic characteristics, and treatment along with survival data were recorded. Race was categorized into white, black, and other (American Indian/AK Native, Asian/Pacific Islander). Extrathyroidal extension was divided into minimal extension and gross extension. Cervical lymph node metastasis was determined by derived AJCC N stage, 6th ed (2004+), which includes N0 (without nodal metastasis) and N1 (N1a, N1b, and N1). N1a means nodal metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes). N1b represents nodal metastasis to unilateral, bilateral, or contralateral cervical or cervical or superior mediastinal lymph nodes. N1 (NOS) means regional nodal metastasis. Patients with multiple primary tumors, tumors in both sides of thyroid lobes, non-positive histology, age < 18 years, unknown or indefinite data of interest were excluded. Only patients with unilateral PTMC were included.

Statistical Analysis

Age and year of diagnosis were expressed as median (upper and lower quartile) for its skewed distribution and analyzed with Mann-Whitney U test. Category variables were presented as percentage and analyzed using chi-square test. The cancer specific survival (CSS) and overall survival (OS) were estimated by the Kaplan–Meier curves and compared by log-rank tests. The Cox proportional hazard model was established to estimate risk factors for CSS and OS with hazard ratio (HR) and a 95% confidence interval (CI). Propensity score matching (PSM) was performed using R software (ver. 3.3.3, http://www.r-project.org/) of package ‘MatchIt’. One-to-one matching with a caliper of 0.1 was used to balance demographic, pathologic and treatment covariates between TL and TT (11). The matched variables included age, year of diagnosis, sex (male vs. female), multifocality (solitary and multiple nodules), extrathyroidal extension (no vs. yes), cervical lymph node metastasis (no vs. yes), distant metastasis (no vs. yes), and radioactive iodine (RAI). Subgroup analyses stratified by clinicopathologic characteristics were performed (12). All statistical differences were set at a two-sided p value < 0.05. The other data were analyzed by Stata software (Stata/MP ver. 14.2, StataCorp., College Station, TX), and GraphPad Prism (ver 7.0, GraphPad Software, Inc).

RESULTS

Patient Characteristics

The flow chart of selection was shown in Supplementary Figure 1. Finally, a total of 31167 patients with unilateral PTMC were enrolled, including 6929 (22.2%) undergoing TL and 24238 (77.8%) undergoing TT (Table 1). The following characteristics of patients were more likely to present with TT compared with TL: younger age, later year of diagnosis, female sex, tumors of multifocality, extrathyroidal extension (minimal and gross extension), CLNM (N1a, N1b and N1), distant metastasis, and treatment with RAI (Table 1).

Predictors for CSS and OS of Patients With PTMC

Results showed that increasing age, gross extrathyroidal extension, N1a, N1b, distant metastasis, treatment with RAI, and chemotherapy were associated with compromised CSS in PTMC patients with HR (95% CI) of 1.12 (1.09-1.14), 2.60 (1.22-5.56), 4.69 (1.92-11.5), 10.11 (4.64-22.03), 24.54 (11.17-53.89), 2.56 (1.25-5.25) and 14.10 (3.03-58.09) compared with the
corresponding counterparts in the multivariate Cox regression (Table 2). In addition, increasing age, male sex, black race, tumors of gross extrathyroidal extension, N1a, N1b, N1 (NOS), distant metastasis, and treatment with chemotherapy were associated with compromised OS in PTMC patients with HR (95% CI) of 1.10 (1.09-1.10), 1.68 (1.41-2.00), 1.99 (1.54-2.56), 1.67 (1.15-2.41), 1.29 (0.85-1.94), 2.40 (1.68-3.43), 6.19 (3.54-10.82), and 3.64 (1.12-11.80) relative to the corresponding groups after adjustment (Table 2).

In the univariate Cox regression analysis, TT was associated with improved OS compare with TL with HR (95% CI) of 0.74 (0.62-0.88) (Supplementary Table 1). In the multivariate Cox regression model, there was a trend toward a better prognosis in CSS and OS of TT over TL with HR (95% CI) of 0.53 (0.25-1.12) and 0.86 (0.72-1.04), respectively. However, the differences were not statistically different (Table 2).

Kaplan–Meier curves showed no differences in CSS between the TT and TL groups (Figure 1A). However, the median OS of TT was significantly longer than that of TL before matching (Figure 1B). After balancing the baseline characteristics between TL and TT, the differences between the two groups were significantly reduced (Supplementary Figure 2). The matched process yielded a total of 6929 paired cases. The differences in baseline covariates were well balanced after matching (Supplementary Table 2). However, there were no significant differences in CSS and OS between patients with TT and TL (Figures 2A, B).

We expected that patients with risk clinicopathologic characteristics may benefit from TT. Patients with tumors of multifocality can gain improved CSS from TT over TL (p = 0.049) after matching (Figure 3A). In addition, patients with tumors of extrathyroidal extension and CLNM showed marginally improved CSS from TT over TL (p = 0.050 and 0.054, respectively) (Figures 3B, C).

### Subgroup Analysis by Multivariate Cox Regression Analysis

In consideration of the trend toward improved prognosis from TT, we further performed subgroup analysis to identify those who might benefit from TT over TL. Compared with TL, TT was associated with improved CSS for patients < 55 years, those with

### TABLE 1 | The clinicopathologic features of PTMC patients treated with TL versus TT.

| Variables                  | TL (n = 6929) n (%) | TT (n = 24238) n (%) | P-value |
|----------------------------|---------------------|----------------------|---------|
| Age (year)                 | 51 (41-61)          | 49 (40-58)           | <0.001  |
| <55                        | 4179 (60.3)         | 15762 (65.0)         | <0.001  |
| ≥55                        | 2750 (39.7)         | 8476 (35.0)          |         |
| Year of diagnosis          | 2010 (2007-2013)    | 2011 (2008-2013)     | <0.001  |
| Sex                        |                     |                      | <0.001  |
| Male                       | 1322 (19.1)         | 4029 (16.6)          |         |
| Female                     | 5607 (80.9)         | 20209 (83.4)         |         |
| Race                       |                     |                      | 0.221   |
| White                      | 5753 (83.0)         | 20316 (83.8)         |         |
| Black                      | 463 (6.7)           | 1591 (6.6)           |         |
| Other                      | 713 (10.3)          | 2331 (9.6)           |         |
| Multifocality              |                     |                      |         |
| No                         | 5705 (82.3)         | 14355 (69.2)         | <0.001  |
| Yes                        | 1224 (17.7)         | 9883 (40.8)          |         |
| Extrathyroidal extension   |                     |                      | 0.221   |
| No                         | 6805 (98.2)         | 22527 (92.9)         | <0.001  |
| Yes                        | 95 (1.8)            | 866 (3.6)            |         |
| Gross extension            | 68 (1.0)            | 845 (3.5)            |         |
| CLNM                       |                     |                      |         |
| No                         | 6814 (98.3)         | 20758 (95.6)         | <0.001  |
| Yes                        | 6 (0.1)             | 58 (0.2)             |         |
| Histotype                  |                     |                      | 0.121   |
| PTC                        | 4842 (69.9)         | 17171 (70.8)         |         |
| FVPTC                      | 2087 (30.1)         | 7067 (29.2)          |         |
| RAI                        | 1682 (95.0)         | 15931 (65.7)         | <0.001  |
| Yes                        | 347 (5.0)           | 8307 (34.3)          |         |
| Chemotherapy               |                     |                      | 0.354   |
| No                         | 6925 (99.9)         | 24215 (99.9)         |         |
| Yes                        | 4 (0.1)             | 23 (0.1)             |         |

Age and year of diagnosis were expressed as median with interquartile, other variables were expressed as n (%). PTMC, papillary thyroid microcarcinoma; TL, Thyroid lobectomy; TT, total thyroidectomy; CLNM, cervical lymph node metastasis; PTC, papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; RAI, radioactive iodine.
TABLE 2 | The predictors for CSS and OS of PTMC patients by multivariate Cox regression.

| Category                  | Cancer specific survival | Overall survival |
|---------------------------|--------------------------|------------------|
|                           | HR (95% CI)              | P-value          | HR (95% CI)              | P-value          |
| Age (year)                | 1.12 (1.09-1.14)         | <0.001           | 1.10 (1.09-1.10)         | <0.001           |
| Diagnosis year            | 0.83 (0.74-0.92)         | 0.001            | 0.95 (0.92-0.98)         | 0.002            |
| Sex                       | Ref                      | 0.889            | Ref                      | <0.001           |
| Female                    | 1.04 (0.57-1.91)         | 1.68 (1.41-2.00) | Ref                      | 0.351            |
| Race                      | Ref                      | Ref              | Ref                      | Ref              |
| White                     | 0.96 (0.23-4.00)         | 0.954            | 1.99 (1.54-2.56)         | <0.001           |
| Black                     | 0.87 (0.35-2.18)         | 0.762            | 0.71 (0.51-0.98)         | 0.038            |
| Multifocality              | Ref                      | 0.332            | Ref                      | 0.92 (0.77-1.10) | 0.351 |
| No                        | 0.75 (0.42-1.34)         | 0.98 (0.56-1.71) | 0.90 (0.56-1.71)         | 0.930            |
| Extrathyroidal extension   | Ref                      | 0.334            | 1.67 (1.15-2.41)         | 0.006            |
| No                        | 1.71 (0.58-5.07)         | 1.67 (1.15-2.41) | 1.67 (1.15-2.41)         | 0.006            |
| Gross extension            | 2.60 (1.22-5.56)         | 0.14             | 2.60 (1.22-5.56)         | 0.014            |
| CLNM                      | Ref                      | 0.334            | Ref                      | 0.92 (0.77-1.10) | 0.351 |
| No                        | 4.69 (1.92-11.5)         | 1.29 (0.85-1.94) | 0.98 (0.56-1.71)         | 0.228            |
| N1a                       | 10.11 (4.64-22.03)       | 2.40 (1.88-3.43) | 2.40 (1.88-3.43)         | <0.001           |
| N1b                       | 2.54 (0.55-11.70)        | 2.17 (1.22-3.87) | 2.17 (1.22-3.87)         | 0.009            |
| N1 (NOS)                  | Ref                      | 0.231            | Ref                      | 0.231            |
| Distant metastasis        | Ref                      | <0.001           | Ref                      | <0.001           |
| No                        | 24.54 (11.17-53.89)      | 6.19 (3.54-10.82)| 6.19 (3.54-10.82)        | <0.001           |
| Histotype                 | Ref                      | 0.736            | Ref                      | 0.127            |
| PTC                       | 0.90 (0.49-1.67)         | 1.14 (0.96-1.35) | 1.14 (0.96-1.35)         | 0.127            |
| FVPTC                     | 0.90 (0.49-1.67)         | 1.14 (0.96-1.35) | 1.14 (0.96-1.35)         | 0.127            |
| RAI                       | Ref                      | 0.111            | Ref                      | 0.116            |
| No                        | 2.56 (1.25-5.25)         | 0.83 (0.67-1.04) | 0.83 (0.67-1.04)         | 0.116            |
| Yes                       | Ref                      | 0.001            | Ref                      | 0.031            |
| Chemotherapy              | 14.10 (3.03-65.70)       | 3.64 (1.12-11.80)| 3.64 (1.12-11.80)        | 0.031            |
| No                        | Ref                      | Ref              | Ref                      | Ref              |
| Surgery                   | TL                       | 0.095            | TT                       | 0.095            |
| TL                        | 0.53 (0.25-1.12)         | 0.86 (0.72-1.04) | 0.86 (0.72-1.04)         | 0.116            |

PTMC, papillary thyroid microcarcinoma; HR (95% CI), hazard ratio (95% confidence interval); CLNM, cervical lymph node metastasis; PTC, papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; TL, thyroid lobectomy; TT, total thyroidectomy; RAI, radioactive iodine.

The Prognosis of PTMC With Two or More Risk Clinicopathologic Factors

As shown above, PTMC patients with one risk factor gained survival benefit from TT. It’s interesting to investigate the prognosis of patients with multiple risk factors. In the multivariate Cox regression model, TT can significantly improve CSS of patients with tumors of multifocality & gross extrathyroidal extension, multifocality & N1b, multifocality & extrathyroidal extension & CLNM, extrathyroidal extension & CLNM, or CLNM & age < 55 years compared with TL with HR (95% CI) of 0.13 (0.02-0.82), 0.04 (0.004-0.32), 0.08 (0.01-0.69), 0.13 (0.02-0.73), and 0.10 (0.01-0.82), respectively. Of patients with tumors of multifocality & N1b, TT was associated with improved OS compared with TL with HR (95% CI) of 0.18 (0.04-0.96) (Table 4).

Consistently, in the matched cohort, TT was associated with improved CSS of patients with tumors of multifocality & CLNM (Figure 4A), extrathyroidal extension & CLNM (Figure 4B), or multifocality & extrathyroidal extension & CLNM (Figure 4C) (Log-rank P < 0.05 for all).

DISCUSSION

In the present study, we investigated the extent of surgery and the prognosis of patient with unilateral PTMC. TT was not associated with improved CSS and OS compared with TL in the total population after PSM. However, TT predicted better CSS for patients < 55 years, those with tumors of gross extrathyroidal extension, N1b, and not receiving RAI. After balancing the covariates between the TL and TT groups, we found that TT can improve CSS for patients with tumors of gross extrathyroidal extension, N1b, and those not receiving RAI with HR (95% CI) of 0.13 (0.02-0.81), 0.12 (0.02-0.66), 0.11 (0.02-0.64), 0.34 (0.13-0.90), respectively. TT was associated with marginally improved OS for patients with N1b,distant metastasis, and non-RAI with HR (95% CI) of 0.30 (0.08-1.08) and 0.06 (0.001-2.94), and 0.84 (0.70-1.02), respectively (Table 3).
multifocality, extrathyroidal extension, and CLNM compared with TL. Importantly, we found that patient with multiple risk clinicopathologic factors like CLNM, extrathyroidal extension, and multifocality were more likely to benefit from TT over TL.

The optimal extent of surgery for PTMC has been controversial. Most of the single institutional studies and meta-analysis failed to discern any differences in prognosis of patients with PTMC underwent TT or TL, which might result from the indolent behavior of PTMC, the short-term follow-up duration, and the relatively small sample size (13–15). There may be a trend toward lower mortality rate of TT than TL. However, the limited number of mortality events prevented establishing a definitive correlation between the extent of surgery and prognosis of patients with PTMC (14).

Previous studies found that the recurrence and survival were not statistically different between PTMC patients undergoing TT and TL by the National Cancer Data Base (1985–1998) (16). However, some variables such as multifocality, extrathyroidal extension, and CLNM compared with TL. Importantly, we found that patient with multiple risk clinicopathologic factors like CLNM, extrathyroidal extension, and multifocality were more likely to benefit from TT over TL.

The optimal extent of surgery for PTMC has been controversial. Most of the single institutional studies and meta-analysis failed to discern any differences in prognosis of patients with PTMC underwent TT or TL, which might result from the indolent behavior of PTMC, the short-term follow-up duration, and the relatively small sample size (13–15). There may be a trend toward lower mortality rate of TT than TL. However, the limited number of mortality events prevented establishing a definitive correlation between the extent of surgery and prognosis of patients with PTMC (14).

Previous studies found that the recurrence and survival were not statistically different between PTMC patients undergoing TT and TL by the National Cancer Data Base (1985–1998) (16). However, some variables such as multifocality, extrathyroidal extension, and CLNM compared with TL. Importantly, we found that patient with multiple risk clinicopathologic factors like CLNM, extrathyroidal extension, and multifocality were more likely to benefit from TT over TL.
TABLE 3 | The subgroup analysis of the prognosis of PTMC patients treated with TT versus TL by multivariate Cox regression.

| Category | Cancer specific survival | Overall survival |
|----------|--------------------------|-----------------|
|          | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age < 55 years |  
TL | Ref | 0.028 | Ref | 0.327 |
| TT | 0.13 (0.02-0.81) | 0.82 (0.56-1.22) |
| Gross extrathyroidal extension |  
TL | Ref | 0.014 | Ref | 0.106 |
| TT | 0.12 (0.02-0.66) | 0.42 (0.15-1.20) |
| CLNM (N1b) |  
TL | Ref | 0.014 | Ref | 0.065 |
| TT | 0.11 (0.02-0.64) | 0.30 (0.08-1.08) |
| Distant metastasis |  
TL | Ref | 0.297 | Ref | 0.061 |
| TT | 0.12 (0.002-6.22) | 0.06 (0.001-2.94) |
| Non-RAI |  
TL | Ref | 0.030 | Ref | 0.077 |
| TT | 0.34 (0.13-0.90) | 0.84 (0.70-1.02) |

The multivariate Cox regression was adjusted for all the other covariates.

PTMC, papillary thyroid microcarcinoma; TT, total thyroidectomy; TL, thyroid lobectomy; HR (95% CI), hazard ratio (95% confidence interval); CLNM, cervical lymph node metastasis; RAI, radiotherapy.

TABLE 4 | The prognosis of PTMC patients according to the extent of surgery by subgroup analysis stratified by clinicopathologic factors by multivariate Cox regression.

| Category | Cancer specific survival | Overall survival |
|----------|--------------------------|-----------------|
|          | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Multifocality & gross extrathyroidal extension |  
TL (n = 30) | Ref | 0.030 | Ref | 0.136 |
| TT (n = 526) | 0.13 (0.02-0.82) | 0.36 (0.10-1.37) |
| Multifocality & CLNM (N1b) |  
TL (n = 13) | Ref | 0.003 | Ref | 0.045 |
| TT (n = 754) | 0.04 (0.004-0.32) | 0.18 (0.04-0.96) |
| Multifocality & extrathyroidal extension & CLNM |  
TL (n = 8) | Ref | 0.022 | Ref | 0.100 |
| TT (n = 521) | 0.08 (0.01-0.69) | 0.22 (0.04-1.34) |
| Extrathyroidal extension & CLNM |  
TL (n = 21) | Ref | 0.021 | Ref | 0.061 |
| TT (n = 734) | 0.13 (0.02-0.73) | 0.26 (0.06-1.06) |
| Age < 55 years & CLNM |  
TL (n = 88) | Ref | <0.001 | Ref | 0.189 |
| TT (n = 2675) | 0.10 (0.01-0.82) | 0.39 (0.09-1.60) |

The multivariate Cox regression was adjusted for all the other covariates in each category.

PTMC, papillary thyroid microcarcinoma; TT, total thyroidectomy; TL, thyroid lobectomy; HR (95% CI), hazard ratio (95% confidence interval); CLNM, cervical lymph node metastasis.
extension, pathological type, chemotherapy and RAI were missing or incomplete, and subgroup analysis were not performed. Lee et al. did not find any significant differences in the risk of death and locoregional recurrence between TT and TL in a matched cohort with 506 paired PTMC patients from 1986 to 2006 (15). Some single institutional studies found that the recurrence rate of patients undergoing TT was similar with those undergoing TL (3, 15). However, a recent meta-analysis showed that TT was associated with lower recurrence rates than TL (14, 17). For PTMC of multifocality, TL may result in a higher rate of thyroid bed and lymph node recurrence than TT (18). The low recurrence rate of TT might result from a more radical resection of the contralateral thyroid lobe and cervical lymph nodes (5, 19), while transient and permanent hypoparathyroidism was higher for TT than TL (5).

We found that patients undergoing TT were more likely to be younger, and present with tumors of multifocality, extrathyroidal extension, CLNM, and distant metastasis. These features were associated with nodal metastasis, tumor recurrence, and unfavorable prognosis of patients (7, 8, 20). We found that patients undergoing TT showed a trend toward improved CSS and OS compared with patients receiving TL. Relative treatment effects may vary according to the heterogeneous study population, certain high-risk subsets may benefit most from the treatment (21). We thus expected that a subpopulation of PTMC patients may benefit from TT.

The subgroup analysis revealed that patients < 55 years, those with tumors of gross extrathyroidal extension had improved CSS from TT compared with TL. Younger age and extrathyroidal extension were risk factors for CLNM (7, 8). Of note, TT failed to improve the prognosis of patients with minimal extrathyroidal extension and N1a. For patients with N1b, TT significantly improved CSS of patients compared with TL. These findings highlighted the importance of detecting nodal metastasis in the lateral neck. The preferred hierarchy of treatment for PTC with distant metastasis includes TT, nodal dissection, postoperative RAI therapy, and thyrotropin inhibition therapy. As for refractory disease, kinase inhibitors were recommended (4). We found that patients with distant metastasis may benefit from TT over TL. However, the number of patients with distant metastasis was relatively small and the result needs to be validated in the following studies. The present study found that patients not receiving postoperative RAI might benefit from TT with improved CSS compared with TL. TT might facilitate to eradicate disease recurrence of the contralateral lobe, and potential metastatic lymph nodes, which was beneficial for those not receiving RAI.

We did not observe any differences in the prognosis between TT and TL for PTMC patient with multifocality in the multivariate model, which was consistent with a previous study (22). However, after PSM between TL and TT, TT showed improved CSS for multifocal tumor in unilateral PTMC patients compared with TL, while the OS was similar. TL may be a safe treatment approach for selected unilateral PTMC patients with multifocal and node-negative tumors (3), which was consistent with our results. The prognostic significance of multifocal tumors in PTC remains controversial (23). However, when tumors of multifocality together with CLNM, extrathyroidal extension, or both were presented, TT was associated with improved CSS compared with TL. Therefore, a more radical surgical treatment may be considered for tumors with more risk factors.

The study should be interpreted in consideration of several limitations. First, selection bias was inevitable even though we adjusted the covariates and performed PSM analysis. In addition, data like disease recurrence and thyroid-stimulating hormone inhibition were not available in the database. Additionally, the results of subgroup analysis should be interpreted with caution for the limited samples and events evaluated. Last but not least, the occult thyroid cancer in the contralateral thyroid lobe and the exact number of metastatic lymph nodes may also influence the outcome. The strengths of this study lie in the latest and largest samples to date, comprehensive variables adjusted, and subgroup analysis analysis with PSM analysis.

In conclusion, we for the first time investigated the association between the extent of thyroid surgery and prognosis of unilateral PTMC patients. The present results suggested that there was no statistical difference in prognosis between TL and TT for unilateral PTMC patients. TL is appropriate for unilateral PTMC without risk factors. However, PTMC patients with risk features such as a younger age, multifocality, gross extrathyroidal extension, and N1b may benefit from TT over TL, especially for those with multiple risk factors. These findings may have an impact on the treatment of unilateral PTMC. Large sample size and long-term follow-up studies are warranted to validate the present findings.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material/Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

HZ: conception, data acquisition. HZ and LC: data analysis and drafting the article. HZ and LC: revised it critically for important intellectual content. HZ: investigation, project administration, and supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the Fundamental Research Funds for the Central Universities (grant number 2042020k0063).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.655608/full#supplementary-material
REFERENCES

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA Cancer J Clin (2016) 66:115–32. doi: 10.3322/caac.21551
2. Davies L, Welch HG. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. Jama (2006) 295:2164–7. doi: 10.1001/jama.295.18.2164
3. Jeon YW, Gwak HG, Lim ST, Schneider J, Suh YJ. Long-Term Prognosis of Unilateral and Multifocal Papillary Thyroid Microcarcinoma After Unilateral Lobectomy versus Total Thyroidectomy. Ann Surg Oncol (2019) 26:2952–8. doi: 10.1245/s10434-019-07482-w
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016) 26:1–133. doi: 10.1089/thy.2015.0020
5. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A Comparison of Lobectomy and Total Thyroidectomy in Patients With Papillary Thyroid Microcarcinoma: A Retrospective Individual Risk Factor-Matched Cohort Study. Eur J Endocrinol (2017) 176:371–8. doi: 10.1530/EJE-16-0845
6. Zhao H, Li H. Meta-Analysis of Ultrasound for Cervical Lymph Nodes in Papillary Thyroid Cancer: Diagnosis of Central and Lateral Compartment Nodal Metastases. Eur J Radiol (2019) 112:1–21. doi: 10.1016/j.ejrad.2019.01.006
7. Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, et al. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Microcarcinoma: A Study of 1066 Patients. J Clin Endocrinol Metab (2012) 97:1250–7. doi: 10.1210/jc.2011-1546
8. Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, et al. Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma. Thyroid (2016) 26:807–15. doi: 10.1089/thy.2015.0429
9. Lee J, Song Y, Soh EY. Central Lymph Node Metastasis Is an Important Prognostic Factor in Patients With Papillary Thyroid Microcarcinoma. J Korean Med Sci (2014) 29:14–52. doi: 10.3346/jkms.2014.29.1.14
10. Vargas-Pinto S, Romero Arenas MA. Lobectomy Compared to Total Thyroidectomy for Low-Risk Papillary Thyroid Cancer: A Systematic Review. J Surg Res (2019) 242:244–51. doi: 10.1016/j.jss.2019.04.036
11. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 46:399–424. doi: 10.1080/10826090.2011.565180
12. Zhang S, Liang F, Li W, Hu X. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors. J Clin Oncol (2015) 33:1697–702. doi: 10.1200/JCO.2014.59.8862
13. Dobrinja C, Pastoricchio M, Troian M, Da Canal F, Bernardi S, Fabris B, et al. Partial Thyroidectomy for Papillary Thyroid Microcarcinoma: Is Completion Total Thyroidectomy Indicated? Int J Surg (2017) 41 Suppl 1:S34–9. doi: 10.1016/j.ijsu.2017.02.012
14. Macedo FL, Mittal VK. Total Thyroidectomy versus Lobectomy as Initial Operation for Small Unilateral Papillary Thyroid Carcinoma: A Meta-Analysis. Surg Oncol (2015) 24:147–52. doi: 10.1016/j.suronc.2015.04.005
15. Lee J, Park JH, Lee CR, Chung WY, Park CS. Long-Term Outcomes of Total Thyroidectomy versus Thyroid Lobectomy for Papillary Thyroid Microcarcinoma: Comparative Analysis After Propensity Score Matching. Thyroid (2013) 23:1408–15. doi: 10.1089/thy.2012.0463
16. Biliomaria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of Surgery Affects Survival for Papillary Thyroid Cancer. Ann Surg (2007) 246:375–81; discussion 381–374. doi: 10.1097/SLA.0b013e3181469739
17. Zheng W, Li J, Lv P, Chen Z, Fan P. Treatment Efficacy Between Total Thyroidectomy and Lobectomy for Patients With Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis. Eur J Surg Oncol (2018) 44:1679–84. doi: 10.1016/j.ejso.2018.08.004
18. Feng JW, Pan H, Wang L, Ye J, Jiang Y, Qu Z. Determine the Optimal Extent of Thyroidectomy and Lymphadenectomy for Patients With Papillary Thyroid Microcarcinoma. Front Endocrinol (Lausanne) (2019) 10:363. doi: 10.3389/fendo.2019.00363
19. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total Thyroidectomy versus Lobectomy in Conventional Papillary Thyroid Microcarcinoma: Analysis of 8,676 Patients at a Single Institution. Surgery (2017) 161:485–92. doi: 10.1016/j.surg.2016.07.037
20. Adam MA, Pura J, Gu L, Dinan J, Tyler DS, Reed SD, et al. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival: An Analysis of 61,775 Patients. Ann Surg (2014) 260:601–5. doi: 10.3346/jkms.2014.29.1.48
21. Pocock SJ, Stone GW. The Primary Outcome Is Positive—Is That Good Enough? N Engl J Med (2016) 375:971–9. doi: 10.1200/JCO.2014.59.8862
22. Harries V, Wang LY, McGill M, Xu B, Tuttle RM, Wong RJ, et al. Should Multifocality be an Indication for Completion Thyroidectomy in Papillary Thyroid Carcinoma? Surgery (2020) 167:10–7. doi: 10.1016/j.surg.2019.03.031
23. Iacobone M, Jansson S, Barczynski M, Goretzki P. Multifocal Papillary Thyroid Carcinoma: A Consensus Report of the European Society of Endocrine Surgeons (Eses). Langenbecks Arch Surg (2014) 399:141–54. doi: 10.1007/s00423-013-1145-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhao and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.